Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
Dry eye disease (DED) is a common eye problem, affecting 5% to 50% of the world population.
Although the disease is not fatal, it substantially reduces quality of life and creates a
high economic burden as high as over 50 billion from a societal perspective. Several
biological tear substitutes (e.g., autologous serum (AS), autologous platelet rich plasma
(APRP), and autologous platelet lysate (APL)) could effectively improve dry eyes, especially
in patients with moderate to severe DED.. However, evidence on their comparative efficacy is
controversial. The objective of the study is to compare the efficacy of 100% APRP with 100%
AS eye drops in patients with moderate to severe DED.